^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    POLE S459F

    i
    Other names: POLE1, DNA Polymerase Epsilon Catalytic Subunit, DNA Polymerase Epsilon Catalytic Subunit A, Polymerase (DNA) Epsilon Catalytic Subunit, DNA Polymerase II Subunit A, Polymerase (DNA Directed) Epsilon Catalytic Subunit, DNA Polymerase Epsilon Catalytic Subunit Protein, Polymerase (DNA Directed) Epsilon
    Entrez ID:
    5426
    Related biomarkers:
    Mutation
    Others
    Associations

    News

    Trials
    over1year
    Deep Amplicon Sequencing of POLE Gene Using fastGEN Technology (EACR 2023)
    Together with other often requested predictive biomarkers, fastGEN kits can be easily implemented in laboratories with Illumina sequencers. A user-friendly and robust bioinformatics pipeline is based on Genovesa fastGEN platform.
    Tumor mutational burden • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • POLE (DNA Polymerase Epsilon)
    |
    TMB-H • POLE mutation • POLE V411L • POLE P286R • POLE S459F
    |
    TruSight Oncology 500 Assay
    over3years
    Clinical and epigenetic features of colorectal cancer patients with somatic POLE proofreading mutations. (PubMed, Clin Epigenetics)
    CRC patients with POLE proofreading mutations are rare. Such mutations are observed in younger individuals, and tumours are primarily located in the right colon. Diagnosis occurs at an earlier stage, and distinct epigenetic alterations may be associated with CD8 cell infiltration.
    Clinical • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • POLE (DNA Polymerase Epsilon) • CD8 (cluster of differentiation 8) • MLH1 (MutL homolog 1)
    |
    KRAS mutation • BRAF mutation • POLE mutation • CD8 positive • POLE V411L • POLE P286R • POLE S459F
    over4years
    [VIRTUAL] Tumor mutational load, microsatellite instability, BRCAness, and actionable alterations in metastatic colorectal cancer: Results from the TRIBE2 study (ESMO-GI 2020)
    "Background In the TRIBE2 study, molecularly unselected and untreated mCRC patients were randomized to receive FOLFOXIRI/bevacizumab (bev) followed by the same agents after disease progression (PD) or FOLFOX/bev followed by FOLFIRI/bev after PD...Legal entity responsible for the study The author. Funding GONO Foundation."
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • POLE (DNA Polymerase Epsilon) • PALB2 (Partner and localizer of BRCA2) • MSH6 (MutS homolog 6) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • ATR (Ataxia telangiectasia and Rad3-related protein) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD50 (RAD50 Double Strand Break Repair Protein) • CHEK1 (Checkpoint kinase 1) • BARD1 (BRCA1 Associated RING Domain 1) • MRE11A (MRE11 homolog, double strand break repair nuclease) • NTRK (Neurotrophic receptor tyrosine kinase) • EMSY (EMSY Transcriptional Repressor BRCA2 Interacting)
    |
    BRAF V600E • KRAS mutation • MSI-H/dMMR • KRAS G12C • HER-2 amplification • BRAF V600 • HER-2 mutation • MET amplification • POLE mutation • KRAS G12 • MSH6 mutation • RAD50 mutation • BRAF mutation + MET amplification • POLE P286R • MSH6 F1040fs • MSH6 expression • POLE S459F
    |
    Avastin (bevacizumab)
    over4years
    [VIRTUAL] Tumor mutational load, microsatellite instability and actionable mutations in metastatic colorectal cancer: Results from the TRIBE2 study. (ASCO 2020)
    "Background: In the TRIBE2 study molecularly unselected and untreated mCRC patients were randomized to receive FOLFOXIRI/bevacizumab (bev) followed by the same agents after disease progression (PD) or FOLFOX/bev followed by FOLFIRI/bev after PD... TML high tumors are not limited to MSI-high ones but showed POLE or MSH6 somatic mutation and shower longer PFS and OS. No differences are reported between TML low and intermediate tumors. Molecular alterations predictive of benefit from targeted strategies currently available are detectable only in a small percentage of mCRCs."
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • POLE (DNA Polymerase Epsilon) • MSH6 (MutS homolog 6) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • KRAS mutation • KRAS G12C • HER-2 amplification • BRAF V600 • HER-2 mutation • MET amplification • POLE mutation • KRAS G12 • MSH6 mutation • KRAS amplification • BRAF mutation + MET amplification • POLE P286R • BRAF amplification • MSH6 F1040fs • MSH6 expression • POLE S459F
    |
    MI Tumor Seek™
    |
    Avastin (bevacizumab)